Cherry-picked sample of patients with tumor fully resected, but none of that for comparators.
Contrary publication summarizes a wide range of issues that questions the validity of the conclusions:
"To conclude, stringently designed and executed prospective randomized clinical trials remain the gold standard for evaluation of efficacy of novel treatments. Control of known, but also unknown, confounders are crucial in clinical trials, and the present analyses of the DCVax-L trial offer neither. Further methodological research and definition of standards that ensure adequate scientific rigor is needed to define the possible role of externally controlled clinical trial data for retrospective analyses or within prospective clinical trials. This concerns both healthcare and regulatory decision making in (neuro-)oncology."
Not my opinion.
Market Data 
Markets 
